IR-1061: Near Infrared Fluorescent Dye for Deep In Vivo Imaging

Principle Overview: Harnessing IR-1061 for Next-Generation NIR-II Imaging

Fluorescence imaging in the near-infrared (NIR) spectrum has redefined the possibilities for deep-tissue visualization, offering high sensitivity, minimal background autofluorescence, and real-time capabilities crucial for biomedical research. Among NIR fluorophores, IR-1061 stands out as a near infrared fluorescent dye that emits in the NIR-II window (1000–1700 nm), the optimal range for deep in vivo imaging due to its low photon scattering and tissue absorption. According to the reference study, IR-1061 achieves a fluorescence peak at 1064 nm and a quantum yield (QY) of 1.70 ± 0.05%, outperforming most other cyanine dyes and inorganic alternatives in both signal clarity and biological compatibility.

IR-1061’s molecular design confers exceptional optical properties while circumventing the long-term retention and excretion challenges faced by inorganic probes. Its hydrophobic cyanine structure, however, presents both opportunities and unique handling requirements. For researchers pursuing in vivo molecular imaging, angiography, and intraoperative guidance, IR-1061—provided by APExBIO—offers a comprehensive solution grounded in advanced material science and rigorous quality control.

Step-by-Step Workflow: Optimal Protocols for IR-1061 Use

Maximizing the performance of IR-1061 in biomedical research demands careful attention to its solubility, encapsulation, and application workflow. Here is a streamlined protocol integrating best practices from the literature and product specifications:

Protocol Parameters

• Stock solution preparation: Dissolve IR-1061 at ≥25.65 mg/mL in DMSO; vortex thoroughly at room temperature for 5–10 minutes to ensure full dissolution, as the dye is insoluble in ethanol and water.
• Liposome encapsulation: For optimal fluorescence intensity, combine IR-1061 with anionic phospholipids at a final dye-to-lipid ratio not exceeding 1:20 (w/w); incubate at 37°C for 30 minutes before purification.
• In vivo imaging: Administer IR-1061-loaded nanoparticles or liposomes intravenously at doses between 1–5 mg/kg; perform imaging within 30 minutes and repeat up to 16 hours post-injection for long-circulation studies.

It is critical to freshly prepare IR-1061 solutions prior to use, as the compound’s stability in solution is time-limited. Store unused solid at -20°C, tightly sealed and desiccated, as recommended by APExBIO.

Key Innovation from the Reference Study

The reference study introduced a rational approach for maximizing NIR-II fluorescence by optimizing the encapsulation of IR-1061 within liposomes. The authors systematically varied liposome charge and IR-1061 loading to reveal two critical insights:

• Charge-Dependent Encapsulation: Anionic liposomes exhibited superior encapsulation efficiency and fluorescence output compared to cationic or neutral liposomes, attributed to favorable electrostatic interactions with the hydrophobic dye.
• Concentration-Dependent Aggregation: IR-1061 exists in both free and aggregated states within liposomes; excessive dye loading induces aggregation, quenching fluorescence. Maintaining a low dye-to-lipid ratio preserves optical performance.

These findings translate into practical assay choices: always select anionic carriers for encapsulation and empirically optimize dye concentration to avoid aggregation-induced quenching. This strategy is essential for applications demanding high spatial resolution and prolonged circulation, such as systemic angiography and hemodynamic studies in murine models.

Comparative Advantages & Advanced Applications

IR-1061’s unique combination of deep tissue penetration, high QY, and biocompatibility positions it as a leading fluorescent dye for in vivo imaging. Unlike inorganic NIR-II probes—such as quantum dots or rare-earth nanoparticles, which may exhibit slow excretion and potential toxicity—IR-1061’s organic nature supports safer and more clinically translatable workflows.

In complementary research, IR-1061’s performance in deep molecular imaging is further highlighted, with advanced encapsulation strategies ensuring robust signal even in complex tissue environments. These workflows underscore the dye’s suitability for:

• High-resolution vascular imaging and systemic angiography
• Real-time intraoperative guidance for tumor resection
• Longitudinal monitoring of hemodynamics and vascular remodeling
• Development of targeted nanoparticles for dual imaging and therapy

Comparatively, the polystyrene nanoparticle encapsulation approach addresses dye aggregation and enhances in vivo brightness, while the PEG-b-PCL micelle system streamlines nanoparticle preparation and improves clinical safety profiles. These studies collectively extend and enrich the protocol options for researchers utilizing IR-1061 across various platforms.

Workflow Enhancements: Troubleshooting & Optimization Tips

Despite its robust optical properties, realizing the full potential of IR-1061 in experimental workflows requires vigilance in handling, formulation, and imaging conditions. Below are targeted troubleshooting strategies:

• Signal Loss Due to Aggregation: If fluorescence intensity decreases with increased dye loading, reduce the IR-1061 concentration or increase the carrier volume. Aggregate formation is a well-documented source of quenching (reference study).
• Poor Solubility in Final Formulation: Always dissolve IR-1061 in DMSO before mixing with lipids or polymers. Do not attempt to dissolve directly in aqueous buffers; intermediate dilution in ethanol or water will precipitate the dye.
• Rapid Photobleaching: Minimize exposure to ambient light during sample preparation and storage. If extended imaging is required, consider encapsulating IR-1061 in a polymer matrix, as demonstrated in nanoparticle-based formulations.
• Batch Variability: Rely on products from trusted suppliers like APExBIO, which performs HPLC, NMR, and MSDS quality checks, to ensure batch-to-batch consistency.

For high-throughput or clinical-adjacent studies, the integration of biodegradable carriers (such as PEG-b-PCL micelles) can further reduce toxicity and streamline regulatory compliance, as reported in recent studies.

Future Outlook: Implications and Expansion

The convergence of advanced encapsulation chemistry and the intrinsic properties of IR-1061 is propelling near infrared fluorescent dye technology into new realms of biomedical research. The reference study demonstrates that rational carrier design—tuning for charge, polarity, and dye loading—yields dramatic gains in imaging sensitivity and duration, with systemic angiography in mice lasting over 16 hours at high spatial resolution.

Looking forward, these insights suggest a robust path for developing multifunctional imaging probes and theranostic nanoparticles. As encapsulation methods become more refined and scalable, and as regulatory frameworks for organic dyes mature, IR-1061 is well-positioned to support a new generation of precise, minimally invasive diagnostics and intervention strategies. Continued cross-validation with complementary encapsulation systems, as outlined in the referenced articles, will further cement IR-1061’s role as a gold-standard fluorescent dye for in vivo imaging and molecular imaging in both preclinical and translational settings.